Anaplastic Lymphoma Kinase (ALK) Mutation-Targeting Treatment With Alectinib in Lung Adenocarcinoma and Primary Cutaneous Marginal Zone B-Cell Lymphoma

Sethi Ashish; Robin R Rodriguez; Purva Sethi; Fang Yu; Moses Raj

doi:10.7759/cureus.29922

Anaplastic Lymphoma Kinase (ALK) Mutation-Targeting Treatment With Alectinib in Lung Adenocarcinoma and Primary Cutaneous Marginal Zone B-Cell Lymphoma

Cureus. 2022 Oct 4;14(10):e29922. doi: 10.7759/cureus.29922. eCollection 2022 Oct.

Authors

Sethi Ashish¹, Robin R Rodriguez², Purva Sethi³, Fang Yu⁴, Moses Raj⁵

Affiliations

¹ Medical Oncology, Allegheny Health Network, Pittsburgh, USA.
² Oncology, Allegheny Health Network, Pittsburgh, USA.
³ Research, Butler Health System, Butler, USA.
⁴ Medical Oncology, University of Pittsburgh, Pittsburgh, USA.
⁵ Hematology & Oncology, Allegheny Health Network, Pittsburgh, USA.

Abstract

Lung adenocarcinoma or non-small cell lung cancer (NSCLC) represents one of the most diagnosed cancers worldwide. Anaplastic lymphoma kinase (ALK) mutation, a tyrosine kinase and ALK fusion or rearrangement oncogene, has been found rarely in patients with NSCLC. Newer treatment modalities with different ALK inhibitors in targetable specific ALK mutations have recently made great strides in the management of NSCLC patients. We present a case of NSCLC harboring ALK mutation with primary cutaneous marginal zone B-cell lymphoma (PCMZL) treated with adjuvant chemotherapy with pemetrexed and cisplatin, and ALK-echinoderm microtubule-associated protein-like 4 (EML4)-targeting treatment alectinib.

Keywords: acletinib; adaura trials; alk inhibitor; alk mutation; central nervous system metastasis; non-small-cell lung carcinoma (nsclc); primary cutaneous b-cell lymphoma; targeted therapy; tyrosine kinase inhibitors (tki).

Publication types

Case Reports